Ignite Creation Date:
2025-12-24 @ 4:09 PM
Ignite Modification Date:
2026-01-04 @ 4:44 AM
Study NCT ID:
NCT02538666
Status:
COMPLETED
Last Update Posted:
2023-01-05
First Post:
2015-08-26
Is NOT Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
An Investigational Immuno-therapy Study of Nivolumab, or Nivolumab in Combination With Ipilimumab, or Placebo in Patients With Extensive-Stage Disease Small Cell Lung Cancer (ED-SCLC) After Completion of Platinum-based Chemotherapy
Sponsor:
Bristol-Myers Squibb
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2015-10-13
Start Date Type:
ACTUAL
Primary Completion Date:
2018-10-01
Primary Completion Date Type:
ACTUAL
Completion Date:
2021-11-11
Completion Date Type:
ACTUAL
First Submit Date:
2015-08-26
First Submit QC Date:
None
Study First Post Date:
2015-09-02
Study First Post Date Type:
ESTIMATED
Results First Submit Date:
2019-10-01
Results First Submit QC Date:
None
Results First Post Date:
2019-10-22
Results First Post Date Type:
ACTUAL
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2022-12-13
Last Update Post Date:
2023-01-05
Last Update Post Date Type:
ACTUAL